Known hypersensitivity to either ASA or rivaroxaban.Uncontrollable hypertension with systolic BP/ diastolic BP consistently above180/100mmHg after treatment.Platelet count less than 100,000/mm3 at enrolment or other bleeding diathesis.Advanced kidney disease (recent estimated GFR =4 at entry.Traumatic brain hemorrhage within 1 month of randomization.intracerebral or subarachnoid hemorrhage) Previous spontaneous hemorrhagic stroke (e.g.Subdural hematoma within 12 months of randomization.Extracranial carotid artery disease ipsilateral to the qualifying brain ischemia with a plan for carotid revascularization.Intracranial arterial stenosis secondary to causes other than atherosclerosis.100% stenosis) responsible for the acute brain ischemia Atrial fibrillation or a history of atrial fibrillation.patient with prosthetic mechanical valve, venous thromboembolism, hypercoagulable state Indication for chronic anticoagulation based on guideline recommendations or investigator ́s judgment e.g.Indication for DAPT for > 90 days on guideline recommendations or investigator ́s judgment e.g., cardiac stenting.Written informed consent consistent with local regulations governing research in human subjects.a high-risk TIA defined as TIA with motor and/or speech involvement or.Recent brain ischemia attributed to intracranial atherosclerotic stenosis of 30-99% as evidenced by CT or MR angiography, occurring between 7 to 100 days prior to randomization and consisting of either: Why Should I Register and Submit Results?.
0 kommentar(er)
